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Abstract
Given the importance of microbiology results on patient care, high quality standards are
expected. Internal quality assurance (IQA) could mitigate the limitations of internal quality
control, competency assessment and external quality assurance, adding a longitudinal
insight, including pre- and post-analytical steps. Here, we implemented an IQA program in
our clinical microbiology facilities with blind resubmission of routine samples during 22
months. One-hundred-and-twenty-one out of 123 (98.4%) serological analyses and 112 out
of 122 (91.8%) molecular analyses were concordant. Among the discordances in molecular
biology analyses, 6 results were low positive samples that turned out negative, likely due to
stochastic repartition of nucleic acids. Moreover, one identified retranscription error led us to
implement automated results transmission from the Applied Biosystems instruments to the
laboratory information system (LIS). Regarding Gram stain microscopy, 560 out of 745
(75.2%) of compared parameters were concordant. As many as 67 out of 84 (79.8%) pairs
of culture results were similar, including 16 sterile pairs, 27 having identical identification or
description and semi-quantification and 24 only showing variations in semi-quantification
with identical description or identification of colonies. Seventeen pairs had diverging identifi-
cation or description of colonies. Culture was twice only done for one member of the pairs.
Regarding antibiotic susceptibility testing, a major discrepancy was observed in 5 out of 48
results (10.4%). In conclusion, serological tests were highly reproducible. Molecular diagno-
sis also revealed to be robust except when the amounts of nucleic acids present in the sam-
ple were close to the limits of detection. Conventional microbiology was less robust with
major discrepancies reaching 39.5% of the samples for microscopy. Similarly, culture and
antibiotic susceptibility testing were prone to discrepancies. This work was ground for recon-
sidering multiples aspects of our practices and demonstrates the importance of IQA to com-
plete the other quality management procedures.
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Introduction
Microbiology laboratories are nowadays facing numerous challenges. The spread of antimicro-
bial drugs resistances demands rapid and yet reliable characterization of causative agents to
prevent treatment failures and evitable occurrences of resistances [1–3]. Regular identification
of emerging pathogens [3] and implementation of new molecular techniques [4] bring greater
technical complexity, while prompt results and better cost-efficiency are expected [5–7].
Besides these evolutions, the awareness about medical errors and their consequences empha-
sizes the great importance of quality in health [8,9]. Indeed, clinical laboratories and related
quality management programs have a role in preventing deaths due to evitable medical errors
[10].
Quality management went along a constant evolution from the sixties to reach the current
state of practice [11]. It is now generally accepted [12] and legally prescribed in Switzerland
[13] and in the USA [14] that a minimal quality assurance (QA) program is composed of qual-
ity control (QC), external quality assessment (EQA), standard operating procedure (SOP) and
competency assessment (CA) of coworkers. These procedures, despite being needed and regu-
lated by certification processes such as ISO 15189 [15], have major limitations discussed
below.
First, QC focuses on the intrinsic performances of laboratory tests, reviewing their perfor-
mance (specificity & sensitivity), the regular maintenance of all used materials, the constant
quality of reactants and media, as well as the use of negative and positives controls [12].
Despite their established role, QC are insufficient [11], especially because they do not cover
pre- and post-analytical steps [10,16,17].
EQA includes external audits as well as proficiency testing (PT) with samples sent by refer-
ence nodal laboratories to be analyzed and described [12]. Audits can reveal structural dys-
functions and possible points to improve. PT with unknown samples probes the ability of the
laboratory to treat and characterize samples and to identify pathogens. Both audits and PT
provide valuable information on the functioning of the laboratories but are limited by their
rare occurrence. PT has shown several additional limitations:
• It only partially evaluates pre- and post-analytical steps [18]; for example, PT samples are
often coming in modified forms (e.g. dried, synthetically produced, pre-treated as with
serum samples instead of whole blood), which can prevent their inclusion into regular lines
of sample handling.
• PT are not available for all the different tests offered by our laboratories (for instance no PT
is available for unusual pathogens such as T. whipplei and W. chondrophila) [19].
• It has been shown that their recognition as EQA can lead to falsely reassuring results because
of the extra caution given in their processing [20,21]; indeed, samples labeled as EQA were
shown to provide more reliable results than EQA submitted blindly [22].
Competency assessment (CA) probes the ability of the laboratory personnel to complete
properly their tasks, in good adequacy with SOP. CA programs can be simple, such as direct
observation of technicians and quizzes to complete, or more sophisticated, with for instance,
submission of blind challenge samples [23–28]. Despite the different approaches evaluated in
the literature, most suffer of similar limitations as QC, with a primary focus on individuals per-
forming defined analytical phases and limited insight on the overall quality of laboratory pro-
cesses. CA programs can also certainly be biased when the workers identify the time of
evaluation. Interestingly, blind resubmissions of previously analyzed samples, which is one of
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the methods suggested in literature for CA purposes, seem to suffer of less limitations but are
only seldom used [24].
Internal quality assurance (IQA) programs based on resubmissions of replicated samples
could address the mentioned limitations but lack of supporting definitions and data. The
potential of this type of procedures is recognized by reference organizations such as the Eura-
chem and the Standard Unit, Microbiology Services of Public Health England, which recom-
mend them to assess internally the overall reproducibility of samples testing and handling
[29,30]. However, there is very few original publications in clinical microbiology setting sup-
porting these recommendations, the only ones being the studies conducted in Cambridge in
the nineties by Constantine et al [31] and Gray et al [32]. The authors concluded then that
their works showed the capacity of this system to detect error, highlighted point of improve-
ments and produced relevant data on the reproducibility of their results and the overall quality
of their laboratories [31–33].
Thus, in the present work, we implemented an internal quality assessment program using
blind split samples. This provided data on the reproducibility of the results in our microbiol-
ogy laboratory and helped us to define specific corrective measures.
Materials and methods
Study design
A new IQA procedure was initiated in October 2014 in the three clinical laboratories (serology,
molecular microbiology and conventional microbiology) of the Institute of Microbiology of
the University Hospital of Lausanne (Switzerland). This procedure was designed and imple-
mented by the quality committee of our laboratories and exempted from formal ethic commit-
tee approval based on its regulation regarding quality control studies [34]. Indeed, the scheme
which was applied here is in line with IQA procedure recommended by reference organiza-
tions in routine practice [29,30]. The present work reviews the data gathered over a 22-month
period and evaluated the discrepancies, including their possible origin and their putative clini-
cal impact (see below).
Data collection
The head technicians of our three laboratories were instructed to secretly withdraw samples
out of the already processed ones. In serology and molecular biology laboratories, samples
were chosen to be proportionally representative of the analyses done by our facilities, but also
ideally, to test at least once every test offered by our service. In the classical microbiology labo-
ratory, the head technician generally selected samples that were expected to be challenging,
because they were positive at Gram stain examination of by culture after overnight incubation.
This approach was retained to increase the number of samples for which the adequacy of bac-
terial identification and antibiotics susceptibility could be investigated. The analysis request
forms were replicated with anonymous identification data, which are commonly used in our
institution for clinical research purposes (and thus not assimilated by our technician to a qual-
ity control). Part of the original sample material was taken into a new container and handed
back in secret at the reception of the laboratories. The correspondence between the patient
identification code and the replicate identification code was reported by the head technicians
into a database for later comparison of the results. Results of the two matching samples were
later reported into an Access database and data analyses were conducted with Microsoft Excel
and PRISM (GraphPad Software). All data were processed anonymously.
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Serology and molecular biology
Pairs of serology results were compared for agreement between qualitative results (positive,
indeterminate or negative) and variations in titers when relevant. Similarly, results of qPCR
pairs were compared for differences in (i) qualitative results (positive versus negative), (ii)
number of copies/ml with a margin of acceptance of one log10 between the two results and (iii)
cycle thresholds (Ct) with a margin of acceptance of 3.3 Ct between the two results.
Gram stain examination
Gram stains results were compared regarding semi-quantification of the following parameters:
leukocytes, erythrocytes, epithelial cells, yeasts, Gram-positive cocci, bacilli and diplococci and
Gram-negative cocci, bacilli and coccobacilli. The given interpretations of the Gram results
were also compared when relevant (e.g. suspicion of urines contamination, salivary flora in
sputa, dominant bacterial flora in vaginal swabs). For each parameter, the amplitude of dis-
crepancies was classified according to S1A Table. The most important discrepancy between all
parameters of a pair of samples was recorded. We examined the discrepancies for each param-
eter by linearly weighted Kappa score using GraphPad QuickCalcs website [35]. Kappa score
quantifies the level of correspondence between the ratings of two observers, considering the
natural probability to obtain the same level of concordance only by chance [36]. The weighted
version of Kappa score is used to consider the partial agreements within ordered scales [37].
We adopted the weighting suggested by Cicchetti et Allison [38], which sanctions discrepan-
cies in a linear and not in a quadratic method [39].
Culture and antibiotic susceptibility testing (AST)
Culture results were compared for description and/or identification and semi-quantification
and discrepant cases were described. Quantitative variations were scored according to S1B
Table.
Sets of AST were compared when conducted for the same identified bacteria within a pair
of replicates. Discrepancies were classified following S1C Table. The most significant discrep-
ancy within all tested antibiotics was retained to grade the concordance of the whole AST sets
(e.g. if the AST pairs included a single major discrepancy, the pair of sets were considered as
being majorly discrepant). If AST were not performed for the same species on both replicates,
the cause of the discrepancy was analyzed and described.
Evaluation of clinical impact and putative cause
Interpretation of the clinical impact and putative cause of discordant results was done by a
data review committee of three persons (VS, CD and GG). Discrepancies were classified as
clinically negligible or significant.
Results
Serology
Among 123 serological tests performed twice on 35 sera, a total of 121 (98.4%) were concordant
(Table 1). The first discordant test was a measure of IgG against cytomegalovirus (CMV) by
enzyme immuno-assay (EIA), which was initially positive (index of 1.20) and intermediate when
redone (0.953 for a cut-off for positivity of 1 and for negativity of 0.5). The 123 tests were often
completed within panels of multiple tests detecting antibody reactivity for the same pathogen (in
total 76 different pathogen-specific panels), sometimes reducing the negative impact of discor-
dant results. Thus, this first discordant result was accompanied by electrochemiluminescence
Internal quality assurance in diagnostic microbiology
PLOS ONE | https://doi.org/10.1371/journal.pone.0187263 November 14, 2017 4 / 16
(ECLIA) results, which were both times positive for anti-CMV IgG antibodies (4.84 and 4.78 U/
ml with a cutoff of 1 for positivity). The second discordant pair of results was in the titers of a
syphilis test (TPPA) obtained manually, being twice positive but with titers of 1/2’560 initially
and 1/10’240 when redone. The clinical impact was considered significant in this 2nd case since a
high titer of 1/10’240 generally reflects an acute infection and since this difference of two dilu-
tions might be considered as clinically relevant [40,41]. The limited number of discrepant results
did not allow to investigate the effect of the time delays between the management of the original
samples and their replicates.
Molecular diagnosis
Among 122 tests achieved on 52 replicated samples, 112 (91.8%) molecular tests were concor-
dant (Table 1). Six tests were qualitatively different, being once positive and once negative. Of
the 23 results pairs that included quantitative results, three were diverging in the number of
copies/ml (difference in copies/ml over one log10) and one was quantitatively different only
considering the Ct values (difference in Ct over 3.3).
Regarding the qualitative differences, four discordant molecular results corresponded to
low positive samples (132–175 copies/ml) that turned out to be negative when retested (Fig 1a)
whereas one initially negative result turned out to be positive at 100 copies/ml when retested
(Fig 1b). These 5 discordant results corresponding to EBV in blood (n = 3) and BKV in blood
and urine (n = 2) DNA amplifications could be explained by stochastic repartition of nucleic
acids in the samples. The remaining qualitatively discordant result corresponded to the detec-
tion of a coronavirus in a nasopharyngeal secretion, initially positive at 2280 copies/ml with a
Ct of 36.6, and negative when redone (Fig 1c). Even though all these six qualitative discrepan-
cies were expected since being below the level of sensitivity of our PCRs, we considered that
such results may have a significantly different clinical impact (Table 1). The analysis conducted
Table 1. Overview of results agreements in our different laboratories.
Percentage of agreement Discordant analyses Clinically significant discordances Time between replicates
Mean (SD)
p25/p50/p75 (in hours)
Serology 98.4% 2/123 1/2 28 (19.1)
19.1/24.6/41.6
Molecular diagnosis 91.8% 10/122 6/10
Qualitative results 95.1% 6/122 6/6 182.8 (45.8)
Quantitative results 82.6% 4/23 0/4 169.1/191.5/215.8
Microscopy 75.2%*1 185/745 13/71*2 10.3 (9.5)
Culture 50.0% 43/86 13/43
AST
Aggregated by panels 75.0% 12/48 1/12 5.0/6.5/8.2
Single antibiotics 96.4% 25/759 1/25
This table shows an overview of the agreement, discordance and clinical significance of discordances for the three laboratories. The column “Time between
replicates” indicates the distribution of time, in hours, between the management of the original sample and its replicate. For AST, results were analyzed
once to see whether the panels done for the same bacteria had identical results (Aggregated by panels) and once to see whether every single antibiotic
tested had the same results twice (Single antibiotics).
*1 overall agreement for all parameters;
*2 results aggregated per samples;
SD = standard deviation; p25 = percentile 25; p50 = percentile 50, p75 = percentile 75.
https://doi.org/10.1371/journal.pone.0187263.t001
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on the effect of time on the discrepancy level was inconclusive because of the small number of
discordant results. The average time between original testing and replication was longer for
concordant results than for discrepant.
Concerning the four quantitative discordances out of the 23 samples pairs that included
quantitative results, a Bordetella pertussis detection in a nasopharyngeal secretion was discor-
dant both considering the bacterial load (2700 copies/ml versus 260 copies/ml) and the Ct
values (34.6 versus 39.5) (Fig 1d). However, this difference was not considered clinically signif-
icant (Table 1). A Parainfluenza 2 also tested in a nasopharyngeal secretion was initially
reported at 505’000 copies/ml and then reported at only 50’000 copies/ml when redone, a dif-
ference not considered to be associated with a significant clinical impact; this one log10 differ-
ence in viral load quantification was likely due to a technical error when redone since the CT
difference was of 2.4 (31.0 versus 33.4) (Fig 1e and Table 1). The third quantitatively discor-
dant result corresponded to the detection of HSV-1 in a vaginal swab with a viral load of
9.6×1010 copies/ml versus 1.6×108 copies/ml, a difference identified to be due to a human
Fig 1. Molecular biology results pairs reparation. Straight line represents the line of identity, expressing perfect match. Pointed lines
delaminate a ± 3.3 Ct tolerance margin. Represented are low positive versus negative results (n = 5, diamonds); moderate positive versus
negative results (n = 1, square), quantitative discrepancies with over one log10 difference in copies/ml (straight triangles, n = 3), quantitative
discrepancy with difference over 3.3Ct but less than one log10 (reversed triangle, n = 1); agreeing positive results (rounds, n = 20). 92
negative agreeing results are not represented on this figure. Note that these results here include two negative pairs and one positive pair of
tests that were not quantitatively reported in copies/ml but only reported in Ct number by the laboratory.
https://doi.org/10.1371/journal.pone.0187263.g001
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transcription error since the Ct values were similar (19.8 and 19.0) (Fig 1f). This error was suf-
ficient to lead to a change of process with implementation of automated data transfer from the
PCR automated system to the Laboratory Information System (LIS), but was not considered to
have a significant clinical impact (Table 1). The fourth quantitative discordance had little clini-
cal impact (Table 1) despite the Ct difference (39.1 versus 35.4) since the calculated EBV viral
load exhibited a difference of less than one log10 (182 versus 771 copies/ml) (Fig 1g).
Conventional microbiology
Ninety-seven samples were duplicated and resubmitted to the conventional microbiology lab-
oratory, requiring variable combinations of Gram staining, culture and AST. Four samples
pairs results were excluded of our analysis. Two because they were including only parasites in
stool analyses, too few to be considered; one because it was possibly being subject to an inver-
sion in IQA sample preparation since staining and cultures results were incompatible; one
because the request for analysis forms were not demanding for the same analyses.
Regarding microscopy of the Gram stains, 32 out of 81 (39.5%) pairs exhibited at least one
major discrepancy (Tables 1 and 2), mainly due to discordances in the reported quantities of
red blood cells (19.8%), leukocytes (8.6%) and Gram-positive cocci (8.6%) (Table 2). Major
discordances were observed in 5.3%, 4.9% and 3.7% for Gram-negative coccobacilli, Gram-
negative bacilli and Gram-positive bacilli, respectively (Table 2). Overall agreement of the
microscopy was of 75.2% (560/745) of all evaluated parameters, whereas the occurrence of a
major error occurred in 6.4% of cases (48/745) (Tables 1 and 2). However, this relatively high
overall agreement rate should be weighted by the common negativity of some parameters such
as Gram-positive diplococci (100% of negativity), yeasts (96.3%) and Gram-negative coccoba-
cilli (93.0%). Thus, after excluding those parameters, the obtained overall agreement would
drop significantly from 75.2% to 67.6%. True rate of concordance is better assessed by
weighted Kappa scores, shown in Table 2 for each parameter. As many as 13 out of 71 (18.3%)







Total Rate of double negativity Weighted Kappa
Leukocytes 37 45.7% 29 35.8% 8 9.9% 7 8.6% 81 2.5% 0.49
Erythrocytes 51 63.0% 9 11.1% 5 6.2% 16 19.8% 81 33.3% 0.55
Epithelial cells 58 71.6% 11 13.6% 6 7.4% 6 7.4% 81 60.5% 0.62
GP cocci 49 60.5% 21 25.9% 4 4.9% 7 8.6% 81 46.9% 0.66
GP diplococci 57 100.0% 0 0.0% 0 0.0% 0 0.0% 57 100.0% N.R.
GN cocci 60 93.8% 3 4.7% 0 0.0% 1 1.6% 64 92.2% 0.69
GN bacilli 48 59.3% 18 22.2% 11 13.6% 4 4.9% 81 49.4% 0.63
GN coccobacilli 53 93.0% 1 1.8% 0 0.0% 3 5.3% 57 93.0% N.R.
GP bacilli 69 85.2% 8 9.9% 1 1.2% 3 3.7% 81 70.4% 0.79
Yeasts 78 96.3% 2 2.5% 0 0.0% 1 1.2% 81 96.3% N.R.
Overall 560 75.2% 102 13.7% 35 4.7% 48 6.4% 745
Highest discrepancy 10 12.3% 19 23.5% 20 24.7% 32 39.5% 81
Gram staining of routine samples and IQA samples were compared and discrepancy amplitudes were categorized according to S1B Table for each
parameter. Rate of double negativity represents the proportion of results that were negative for both the routine and IQA sample. Weighted Kappa score
express the level of concordance between two rates, not only due to natural probability of agreement. Score of -1 expresses perfect disagreement; 0
expresses agreement corresponding to random; probability; 1 expresses perfect agreement. [36,37]
GP = Gram-positive; GN = Gram-negative; NR = non-relevant
https://doi.org/10.1371/journal.pone.0187263.t002
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samples exhibiting at least one discrepancy were considered as having a clinically relevant dis-
cordance, corresponding to a rate of 16.0% (13/81) for all Gram stain results investigated
(Table 1). The discrepancies were considered by our experts to be possibly related to reading
or reporting errors in 8 out of 13 significant and in 11 out of 58 negligible discrepant pairs of
samples, while the rest seemed compatible with natural biological variations (e.g. sample and
coloration heterogeneity). It should also be noted that for two samples, the Gram stain reading
was done only for one of the replicates because of pre-analytical disagreement on the aspect of
urine (urines are examined under microscopy only if considered cloudy). Regarding the effect
of the time delay between the management of the original samples and their replicates, no sig-
nificant differences were observed, when comparing the identical and negligible discrepant
results versus the minor and major discrepant results. This absence of difference was recovered
both when comparing all parameters together and bacteria and yeasts only.
Culture results were perfectly identical for 43 pairs of samples, 16 of which were twice sterile
(Tables 1 and 3). For 24 other pairs of samples, the results showed only negligible or minor dis-
crepancies within semi-quantitative scoring of similarly identified or described colonies,
whereas 17 pairs showed discrepancies within the identification or description of colonies, as
detailed in Table 3. To be noted, two pairs of samples for which cultures were accomplished
only for one member of the pair: once due to diverging microscopy results with a potentially
significant impact and once to an error in procedure with negligible impact (Table 3). Also
noteworthy, three cases in which the differences in microscopy results motivated the addi-
tional inoculation of Gram-positive selective agar, explaining why supplementary clinically-
significant strains (Enterococcus faecalis or Staphylococcus aureus) were recovered from cul-
tures (Table 3). Interestingly, when comparing the time delay from original samples processing
to management of the replicates, the delay was significantly longer for samples that included
minor or major discrepancies in culture growth versus the ones that were identical or negligi-
bly discrepant (14.68 hours ± 2.45 versus 9.19 hours ± 1.13, p = 0.039).
Regarding AST panels, at least one major discrepancy was observed in five (10.4%) out of
48 comparable AST panels, whereas 7 (14.6%) included at least one minor discrepancy, the
remaining 36 AST panels (75.0%) being perfectly identical (Table 4). These discordances had
little clinical impact since only one minor discrepancy concerned an antibiotic which would
potentially have been used in this situation (a Pseudomonas aeruginosa in a respiratory sample
which was once susceptible and once intermediate to levofloxacin) (Table 1).
As many as 23 AST panels, done on the patient sample or the IQA replicate, had no match-
ing AST panel for its counterpart, either because of different interpretation of similar culture
results (n = 8) or because of different culture results (n = 15) (Tables 3 and 5). The clinical sig-
nificance of the 8 AST panels not performed in presence of identical culture results is negligi-
ble, especially since 5 of them were accompanied in transmitted results by a comment
suggesting to the clinician to ask for AST via telephone if needed. Nevertheless, this difference
in attitude could possibly influence the clinical interpretation by unexperimented practition-
ers. On the contrary, 14 out of 15 of the identified bacteria that led to diverging presence of
AST were considered as significant (species marked by  in Tables 3 and 5)
When AST were compared individually, each tested antibiotic one by one, the overall agree-
ment was as high as 96.7% (734/759). There were 15 minor (sensitive versus intermediate or
intermediate versus resistant) and 10 major (sensitive versus resistant) discrepancies. Pipera-
cillin-tazobactam was the antibiotic the most often discrepant, with 3 major and 2 minor dis-
crepancies. Detailed analysis of AST results, ordered by antibiotics, is shown in Fig 2, which
represents concordances and discordances for antibiotics tested at least 10 times. All other
results are available in S2 Table.
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Table 3. Culture results: Agreement and description of discrepant cases.
No culture achieved for both replicates 7
Culture achieved only for one replicate 2
Unnecessary cultivation of vaginal swab for the IQA sample, with otherwise agreeing microscopy results
showing no potential pathogen. Difference of procedure considered as of negligible impact.
Respiratory sample was not cultivated for patient’s sample because of microscopy results suggestive of a
contamination, whereas the IQA microcopy results led to cultivation and growth of moderate quantities of
Klebsiella oxytoca * and Escherichia coli * along a physiological mixed oropharyngeal flora. Difference
of procedure considered of significant impact.
Completely identical identification or description and semi-quantification 43
Including completely sterile pairs of culture 16
Identical identification or description, negligible variation in semi-quantification 24
Culture presenting discrepant identification or description 17
Negligible discrepancies 5
Low quantities of C. albicans recovered only in the patient’s respiratory sample but not in the IQA replicate,
with otherwise agreeing results (Staphylococcus aureus and oropharyngeal flora)
Low quantities of C. albicans recovered only in the patient’s respiratory sample, with otherwise agreeing
results (Escherichia coli, yeast other than C. albicans)
Low quantities of Pseudomonas fluorescens * recovered only in the patient’s pharyngeal swab sample,
with otherwise agreeing results (oropharyngeal flora)
Bifidobacterium spp (107 bacteria/ml) recovered only in the patient’s urinary sample, with otherwise
agreeing results (Enterococcus faecalis)
Two strains of Staphylococcus aureus * detected in the respiratory IQA sample, whereas only one strain
was reported in the patient’s sample, with diverging antibiotic susceptibility between the two strains only for
penicillin
Significant discrepancies 12
Similar growth on plates but different interpretation with only a description of the grown colonies for the
patient’s respiratory sample (low quantities of Enterobacteriaceae, 3 different morphologies and
oropharyngeal flora); this mixed bacterial flora turned out to include low quantities of Klebsiella
pneumoniae * and of Enterobacter cloacae * group bacteria, with a physiological oropharyngeal flora,
when the Gram-negative colonies were properly identified for the IQA sample
Similar growth but different interpretation with only a partial identification for the patient’s respiratory sample
(low quantifies of Enterobacter cloacae group and 3 other morphologies) which turned out to include low
quantities of Serratia marcescens * when properly identified for the IQA sample
Similar growth but different interpretation with only description for IQA respiratory sample (low quantities of
Gram-negative Enterobacteriaceae with oropharyngeal flora) which turned out to include low quantities of
Escherichia coli * when properly identified for the patient’s sample. This difference of procedure could be
the consequence of differences in the Gram stain results (slightly more abundant leucocytes and Gram-
negative cocci may have motivated formal identification for the patient’s sample)
Low quantities of Escherichia coli * and moderate quantities of Enterococcus faecalis * recovered only
in IQA ascites liquid sample, while initial patient sample was sterile. The Enterococcus grew on a Gram-
positive selective plate only used for the IQA sample because of abundant Gram-positive cocci seen under
microscopy. Possible error in samples handling, during the preparation of the IQA sample, since Gram
results were also discordant
Low quantities of Escherichia coli * recovered only in IQA ascites liquid sample, while patient’s sample
stayed sterile
Escherichia coli * (107 germs/ml) and Enterococcus faecalis (107 germs/ml) recovered only in patient’s
urinary sample, while IQA sample stayed sterile. Suspicion of error in sample handling
Enterococcus faecalis * (105 germs/ml) recovered only in IQA urinary sample, in otherwise agreeing
results (Proteus vulgaris). This difference was explained by the usage of a Gram-positive selective agar
plate since abundant Gram-positive cocci were observed under microscopy for IQA sample
Moderate quantities of Staphylococcus aureus * recovered only in the patient’s sample (ear swab), with
otherwise agreeing results (Pseudomonas aeruginosa). This difference was explained by the usage of
Gram-positive selective agar plate since abundant Gram-positive cocci were observed under microscopy
for the patient’s sample
Low quantities of Escherichia coli * recovered only in the patient’s respiratory sample, in otherwise
agreeing results (Enterobacter cloacae group and Pseudomonas aeruginosa)
(Continued)
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Nine pairs of sample included rapid testing such as tests for C. difficile antigens and induc-
ible beta-lactamase. All these tests were concordant.
Mycobacteria
Five pairs of samples submitted to conventional microbiology or molecular biology laborato-
ries also included auramine stains, culture and AST for mycobacteria. All the results were con-
cordant, showing agreement on two positive samples and three negative samples.
Discussion
This work demonstrates the feasibility and usefulness of an internal quality assurance program
as part of the global quality management in serology, molecular biology and conventional
microbiology laboratories. Looking at the level of agreement of the different laboratories, we
first observe the high robustness of serological tests, which is partially due to automated sys-
tems and commercial kits which are mostly used, enhancing the reproducibility of processes.
Moreover, serological tests are achieved on sera, which are by nature homogenous, limiting
the variability between different fractions of a given sample.
Table 3. (Continued)
Low quantities of Klebsiella oxytoca group, Escherichia coli and C. albicans recovered only in the
patient’s sample (a biliary liquid), with otherwise agreeing results (Enterococcus faecium, Ochrobactrum
spp).
Low quantities of Streptococcus anginosus/milleri group recovered only in the IQA sample (a superficial
wound swab), with otherwise agreeing results (Staphylococcus aureus)
High quantities of Bacteroides fragilis group recovered only in the patient’s urine sample, with otherwise
agreeing results (Escherichia coli and Enterococcus faecalis)
Total 93
* indicates the colonies that led to an AST when present.
https://doi.org/10.1371/journal.pone.0187263.t003
Table 4. Comparison of AST panels accomplished for the same identified bacterial species.
Identical AST results 36 (75.0%)
AST including at least one minor discrepancy 7 (14.6%)
AST including at least one major discrepancy 5 (10.4%)
Total 48
Major and minor categories as defined in S1C Table.
https://doi.org/10.1371/journal.pone.0187263.t004
Table 5. AST panels without panels for the same bacteria in the results of the corresponding sample.
Identical culture results, different interpretation 8
Accompanied by a comment suggesting a request for AST via phone call 5
Not accompanied by a comment 3
Diverging culture results, leading to different AST 15
Strain presence discrepancy considered as negligible in culture (Table 3) 1
Strain presence discrepancy considered as significant in culture (Table 3) 14
Total 23
https://doi.org/10.1371/journal.pone.0187263.t005
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In molecular biology, the usage of IQA samples shows the common occurrence of discrep-
ancies (10/122 analyses, Fig 1). Most discrepant results were due to the stochastic variability of
qPCR occurring around the limit of detection, where by definition qPCRs lose part of their
sensitivity [42]. Accordingly, these discrepancies should not be considered as technical errors
or insufficiencies. Yet, this variability for weakly positive samples may be overlooked by clini-
cians who often give too much importance to negative results, even when the negative predic-
tive value is known to be low (i.e. for M. tuberculosis detection and for Listeria PCR in
cerebrospinal fluid). While such discrepancies are of limited implication in terms of quality
assurance, the single quantitative discrepancy of a 610-folds factor between copies/ml, with
almost identical Ct number, was worrisome. Investigations revealed that this difference was
the consequence of an error in the manual transcription of the result. In this specific situation,
this error did not have clinical impact, since both results would be interpreted as highly posi-
tive by clinicians. However, this error highlighted a weak point in our procedures and led us to
integrate our automated PCR system with a middleware capable of two directions data trans-
fers from the Applied Biosystems PCR machine to the LIS, in order to definitively abolish any
risk of human errors during results retranscription. Made worthy, no false positive seem to
have resulted from PCR contaminations. This is particularly remarkable considering the high
sensitivity of PCR and likely results from the advanced automatization of our qPCR platform
[19]. Moreover, our IQA process proved itself useful to detect potential errors in this
laboratory.
Gram stain reading is well established as a complex procedure that has number of pitfalls
and its poor reliability has been described at multiple occasions [43–47]. It is still worrisome to
observe that almost 40% of the compared results included at least one discrepancy of more than
two relative units, which we categorized as major (Table 2). This rate cannot be directly com-
pared to any other data available in literature, the only similar experiment being the study of
Constantine et al. (14), which had only 2% of discrepancies for microscopy, but using a very dif-
ferent definition of discrepancy which allowed much larger differences in the semi-quantitative
Fig 2. AST agreement, per antibiotics. Counts of concordant pairs of AST results are in green, minor
discrepancies (sensitive versus intermediate or intermediate versus resistant) are in yellow and major
discrepancies (sensitive versus resistant) are in red. Only antibiotics tested more than 10 times are
represented. Complete results are available in S2 Table. AMC = amoxicillin-clavulanic acid; AMK = amikacin;
AMP = ampicillin; AMX = amoxicillin; CAZ = ceftazidime; CIP = ciprofloxacin; CLI = clindamycin;
CLR = clarithromycin; CRO = ceftriaxone; CXM = cefuroxime; ERY = erythromycin; ETP = ertapenem;
FEP = cefepime; FOF = fosfomycin; GEN = gentamicin; IPM = imipenem; LVX = levofloxacin;
MEM = meropenem; NIT = nitrofurantoin; PEN = penicillin; SXT = trimethoprim-sulfamethoxazole;
TEC = teicoplanin; TET = tetracycline; TOB = tobramycin; TZP = piperacillin-tazobactam; VAN = vancomycin.
https://doi.org/10.1371/journal.pone.0187263.g002
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results. The other studies on the reproducibility of Gram stain use very different methodologies,
such as comparison of the concordance between Gram stain and culture results or between dif-
ferent observers reading identical smears, thus providing non-comparable results [44–47].
Observing the results by parameters in Table 2, the repartition of reported results should be
considered. For example, the very high Gram-positive diplococci or yeasts concordance is
associated with a very high level of negativity. Kappa score partially helps to compare parame-
ters between them, taking into account the natural proportion of concordance explained by
random probability [36]. According to this score, we conclude that in our laboratory the
counts of host cells (leukocytes, erythrocytes) is less reliable than the counts of bacteria. This
questions the sense of reporting parameters such as erythrocytes, with such a high level of
variability and low clinical impact. Those data also support the need for continuous staff train-
ing in this domain and the integration of automatization in Gram reading to improve
reproducibility.
In the evaluation of error rates in Gram staining examination, it is important to emphasize
that our study included no gold-standard. Thus, our experts (GGR and CDU) could only sub-
jectively assess the most likely origin of the discrepancies. Errors were typically suspected when
discrepancies were not compatible with biological variations because they were of very large
amplitude or when confusion was suspected (e.g. ++++ Gram-positive cocci versus ++++
erythrocytes). Nevertheless, the factors leading to result heterogeneity and errors are numerous
for Gram stains. Indeed, the important heterogeneity of samples such as sputa or fragments
and the heterogeneity induced by the staining process can already bring a lot of variability
before the reading phase itself, which is a task known as subjective and complex. Moreover,
despite the high proportion of discrepant cases, our experts concluded that most of them
would have no clinical impact, mainly because they involved host cell quantifications and not
detection of bacteria (Table 1). Furthermore, the clinical impact of Gram stains itself is subject
to discussion, as for the diagnosis of pneumonia [48,49]. Nevertheless, if the importance of
Gram results can be relativized, our work also showed that discrepancies in microscopy results
can influence subsequent analytical steps, with significant impact on final culture and AST
results transmitted to the clinicians (Tables 3 and 5).
Reviewing the comments transmitted with the Gram stain results, an interesting observa-
tion was made concerning 4 out of 22 urinary samples that had contradictory comments
which concluded once to negativity and once to positivity for the corresponding replicate.
These discrepancies were caused by relative quantifications of bacteria that were scored “few”
for one sample and “+” or “++” for the other, with an automatic comment announcing positiv-
ity in the second case only. Comparing those results with the culture results performed on the
same samples, all 4 samples were confirmed positive. This observation questions the usefulness
of the “few” category.
The results of culture shown in Table 3, with 12 significant differences out of 84 cultures
pairs (85.7% accuracy), are representative of its complexity. Culture is a dynamic process influ-
enced by many factors, including heterogeneity of samples, Gram stains results, selected cul-
ture media, stochastic growth variability and interpretation of the clinical significance of the
presence of colonies with choices to identify or not the grown colonies. All these factors con-
tribute to explain the observed discrepancies. Better homogenization of the samples, reconsid-
eration of how Gram results are used to select culture media and training of the personnel
concerning analytical choices are all possible ways to improve reliability of the culture steps.
Furthermore, regarding the design of an IQA program, longer time between the treatment of
the original samples and their replicates was in our data associated with higher level of discrep-
ancy in cultures results. Even this is to be expected, it underlines the importance of shortening
the time delay between the inoculation of the original samples and the replicates.
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Interestingly, we observed a low rate of significant discrepancies within the AST performed
on identical bacteria (Table 4, Fig 2 and S2 Table). On the other hand, steps preceding accom-
plishment of AST (Gram staining, cultivation, identification and interpretation of culture)
often influence significantly the AST transmitted to the clinicians (Tables 3 and 5). These
observations make us consider that the accuracy of the analytical phase of AST is satisfactory
and that we should focus on the pre-analytical factors that are influencing their realization. It
could be argued that the clinical information available concerning the IQA samples were dif-
ferent (e.g. the age) or lacking (e.g. the service of hospitalization), influencing the interpreta-
tion of the culture. If this may explain some discrepancies in the interpretation of similar
culture results, discrepancies originating from diverging interpretation of similar cultures con-
cerned only a minority of samples (Table 5).
Our study, which included only a limited number of samples, provided interesting data on
reproducibility. However, samples were not totally chosen in blind but sometimes selected
because they addressed a particular analytical question. For instance, cloudy urinary samples
were preferably chosen over limpid samples and positive samples are certainly over-repre-
sented, increasing the probability of diverging results.
Another limitation of our IQA program concerns specifically the serology laboratory. First,
in this facility, blood samples are coming in gel-based serum separating tubes. They are centri-
fuged and the supernatant is directly transferred into new tubes. This implies that the repli-
cates could only come from already treated samples and that their visual aspect was different
from almost all routine samples. The technicians of this facility are routinely checking anterior
results from the tested patients to integrate the new results within their serological status.
Because we were using a limited pool of anonymous patient profiles, our technicians eventu-
ally faced multiple anterior results corresponding to IQA samples processed earlier. Both the
visual difference of samples and the anterior results from anonymous patient’s profile led to
strong suspicions of the staff working in the serology laboratory about our ongoing experi-
mental IQA process, which finally obliged us to discontinue the IQA in this laboratory. This
specific issue did not concern the two other facilities where our process could be completed in
secret and on samples that were not pretreated. Despite this limitation, we consider that our
process could still have an interest for IQA in serology laboratories, but that it would need to
be partly redesigned. A proposition would be to duplicate samples before their arrival in the
laboratory. It would solve the problem of visual impact and improve the coverage of pre-ana-
lytical steps. It would also be necessary to use more sophisticated fake patient identities, with-
out previous IQA results to prevent their recognition by our coworkers.
Finally, even if our results cover more steps than traditional quality processes, it is still not
covering all steps from prescription to interpretation of results by clinicians. Thus, we intend
to extend this quality assurance project by collaborating with three other Swiss hospital labora-
tories. Each laboratory would challenge the others with split samples sent into containers
accompanied by etiquettes and identifications used by the receiving laboratories for their
external demands. This way, each laboratory would play the role of reference laboratory for
one fourth of all samples. This approach would resolve the limitations of our scheme concern-
ing the pre-treatment of the serology samples, the recognition of the samples and the lack of
reference results. Such interlaboratory shared quality assurance would also help to provide
“external assurance” for some serological and molecular parameters for which there is cur-
rently no EQA available (i.e. Tropheryma whipplei).
In conclusion, this study revealed insightful points to improve and questioned our current
practices, such as the use of Gram results to select culture media. Also, this study confirms the
great interest of an IQA scheme based on split samples reprocessed in blind. It represents only
few hundreds supplementary analyses, on the over 25’000 analyses run every year in our
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laboratory and this allowed us to generate interesting data on our reproducibility. This design
showed itself to be perfectly complementary to other quality management procedures already
ongoing in our laboratory and it should be further developed to better delineate the identified
limitations and to settle its place in the overall quality assurance program.
Notes
Part of this publication was the subject of a master thesis done by Valentin Scherz under the
direct supervision of Professor Greub at the School of Medicine of the University of Lausanne.
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as the quality officer.
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